• Open Daily: 10am - 10pm
    Alley-side Pickup: 10am - 7pm

    3038 Hennepin Ave Minneapolis, MN
    612-822-4611

Open Daily: 10am - 10pm | Alley-side Pickup: 10am - 7pm
3038 Hennepin Ave Minneapolis, MN
612-822-4611
Emerging Drugs and Targets for Alzheimer's Disease: Volume 1: Beta-Amyloid

Emerging Drugs and Targets for Alzheimer's Disease: Volume 1: Beta-Amyloid

Hardcover

Series: Drug Discovery, Book 2

Medical Reference

ISBN10: 1849730636
ISBN13: 9781849730631
Publisher: Royal Society Of Chemistry
Published: May 7 2010
Pages: 342
Weight: 1.40
Height: 1.00 Width: 6.20 Depth: 9.20
Language: English

Alzheimer's disease is the most prevalent neurodegenerative disorder in the elderly. A recent study from the Bloomberg School of Public Health recently estimated that over 26 million people were living with the disease in 2006 and that the global prevalence of the disease will grow to 106 million by 2050. By that time, 43 per cent of those living with the disease will need high-level care, equivalent to that of a nursing home. However, even if modest advances in preventing or delaying the disease's progression were made, it could have a huge impact on global public health. According to this study, interventions that could delay the onset of the disease by as little as one year would reduce the prevalence of the disease by 12 million fewer cases in 2050. These figures reinforce how important it is to find an effective intervention for Alzheimer's disease.

Also in

Medical Reference